atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
A wave of British scientific breakthroughs is poised to transform how prostate cancer is found and treated.
Prostate cancer is the most common cancer in men across the UK, and the second most common cause of cancer deaths after lung cancer. …
Free live virtual Learna Open Day for healthcare professionals considering postgraduate study. See how online study works, view the platform live, and submit questions. Wed 11 Feb, 13:00 GMT.
Read more and register here.
Attendees
Sponsors and Exhibitors
Contact us